Analysts forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post earnings per share (EPS) of ($0.27) for the current quarter, Zacks reports. Three analysts have made estimates for Amicus Therapeutics’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.25). Amicus Therapeutics posted earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year over year growth rate of 34.1%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.
On average, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($1.11). For the next financial year, analysts forecast that the business will report earnings of ($0.76) per share, with EPS estimates ranging from ($1.20) to ($0.29). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The company had revenue of $21.31 million for the quarter, compared to analyst estimates of $18.92 million.
Shares of FOLD traded down $0.41 during midday trading on Friday, hitting $12.21. The company’s stock had a trading volume of 5,674,400 shares, compared to its average volume of 2,577,302. Amicus Therapeutics has a one year low of $11.57 and a one year high of $17.62. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.73 and a current ratio of 10.88. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -4.36 and a beta of 1.26.
In related news, SVP Kurt J. Andrews sold 5,000 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $15.63, for a total transaction of $78,150.00. Following the sale, the senior vice president now owns 40,469 shares in the company, valued at approximately $632,530.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Life Sciences Maste Perceptive acquired 500,000 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, September 12th. The shares were purchased at an average price of $12.00 per share, for a total transaction of $6,000,000.00. The disclosure for this purchase can be found here. Insiders own 2.90% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Massachusetts Financial Services Co. MA grew its position in Amicus Therapeutics by 1.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 776,230 shares of the biopharmaceutical company’s stock worth $12,125,000 after acquiring an additional 10,809 shares during the last quarter. Principal Financial Group Inc. grew its position in Amicus Therapeutics by 7.2% during the 1st quarter. Principal Financial Group Inc. now owns 134,648 shares of the biopharmaceutical company’s stock worth $2,025,000 after acquiring an additional 9,027 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in Amicus Therapeutics by 13,402.9% during the 2nd quarter. Federated Investors Inc. PA now owns 98,031 shares of the biopharmaceutical company’s stock worth $1,531,000 after buying an additional 97,305 shares during the period. Rhumbline Advisers lifted its holdings in Amicus Therapeutics by 5.9% during the 2nd quarter. Rhumbline Advisers now owns 183,812 shares of the biopharmaceutical company’s stock worth $2,871,000 after buying an additional 10,306 shares during the period. Finally, Rothschild Asset Management Inc. lifted its holdings in Amicus Therapeutics by 145.0% during the 2nd quarter. Rothschild Asset Management Inc. now owns 235,513 shares of the biopharmaceutical company’s stock worth $3,679,000 after buying an additional 139,382 shares during the period.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
See Also: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.